SUGAR LAND, Texas, Dec. 9, 2019 /PRNewswire/ -- QuVa Pharma,
Inc. today announced it has signed a production and distribution
agreement with Hibernation Therapeutics for its patented
cardioplegia solution Adenocaine™, the combination of
Adenosine, Lidocaine and Magnesium Sulfate that is used to
intentionally stop the heart from beating during cardiac surgery,
and is immediately taking orders.
"Improved access to Adenocaine has enormous potential to help
health systems and their patients undergoing cardiac
surgery, and represents continued progress of QuVa's larger
commitment to improving access to specialized, ready-to-use product
offerings like those for cardioplegia," said Stuart Hinchen, QuVa Pharma's co-founder and
Chief Executive Officer.
"Expanding quality production and shelf-life of Adenocaine is a
critical component of our commitment to improving heart surgery
outcomes, said Todd Meyerrose, PhD,
CEO of Hibernation Therapeutics. "By exceeding regulatory
standards for pharmaceutical quality with its cGMP manufacturing
capabilities, demonstrating superior product development processes
and offering national distribution across all 50 states, QuVa is an
excellent partner to expand access to our natural, reproducible
form of myocardial protection during invasive procedures."
Peter Jenkins, QuVa's co-founder
and Chief Development Officer, added, "Adenocaine is an important
addition to our comprehensive portfolio of compounded sterile
products (CSPs), as now hospital pharmacies can take advantage of a
sterile, ready-to-use formulation of the Adenosine, Lidocaine and
Magnesium Sulfate combination with important characteristics in
helping hospital pharmacy reduce waste and increase operational
efficiency, like a significantly longer shelf life at room
temperature storage compared to the previously available
QuVa Pharma is a market leader in quality-compliant, compounded
sterile products. All of its existing facilities – in
Sugar Land, Texas; Temple, Texas; and Bloomsbury, N.J. – are in excellent standing
with the FDA and all state regulatory boards of pharmacy.
QuVa Pharma is licensed to supply compounded preparations into all
50 states and has a comprehensive range of ready-to-use compounded
products, including products compounded from bulk drug substances
to alleviate drug shortages.
For product ordering inquiries, please contact QuVa Pharma
Customer Service at 888.339.0874 or via email at:
For media inquiries, please contact:
About QuVa Pharma, Inc.
QuVa Pharma is a nationally recognized,
industry-leading state-of-the-art cGMP compliant 503B FDA registered manufacturing platform and
partner of choice for compliance-oriented healthcare facilities
looking to ensure a quality, safe and consistent supply of
medications. The company offers a broad portfolio of ready-to-use
products across pain management, anesthesia and OR syringes,
anti-infectives, labor and delivery, cardiovascular therapeutic
areas and others. All products are distributed only once
sterility and potency testing is successfully completed, and with
validation supporting appropriate Beyond Use Dating (BUD).
The company is committed to having a patient-first orientation, as
well as a robust product portfolio, leading safety standards, and
collaborative and transparent partnership-oriented customer
service. For more information, please visit
www.quvapharma.com or follow QuVa on LinkedIn at
View original content to download
SOURCE QuVa Pharma, Inc.